Our study indicates a strong association between circulating M-MDSCs (CD45+ CD15− CD14+ CD11b+ CD33+ HLA-DRlow/− cells, Fig. 1A) and clinical prognosis in DLBCL patients. This evidence concerns the gene CD33 and diffuse large B-cell lymphoma.